Neurocrine Biosciences NBIX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $814.5M+1.1% | $805.5M+1.3% | $794.9M+15.6% | $687.5M+20.1% | $572.6M-8.8% | ||
| $13.8M-21.6% | $17.6M+25.7% | $14M+23.9% | $11.3M+22.8% | $9.2M-1.1% | ||
| $800.7M+1.6% | $787.9M+0.9% | $780.9M+15.5% | $676.2M+20.0% | $563.4M-8.9% | ||
| 98.3%+0.5pp | 97.8%-0.4pp | 98.2%-0.1pp | 98.4%0.0pp | 98.4%-0.1pp | ||
| $296.2M+14.7% | $258.2M+3.3% | $250M+2.3% | $244.3M-7.2% | $263.2M+41.8% | ||
| $318.5M+5.5% | $301.8M+3.5% | $291.6M+1.9% | $286.3M+3.5% | $276.5M-3.9% | ||
| $621.1M+4.5% | $594.6M+7.0% | $555.9M+2.6% | $541.9M-1.3% | $549M+13.0% | ||
| $193.4M-8.3% | $210.9M-11.8% | $239M+64.1% | $145.6M+517% | $23.6M-83.4% | ||
| 23.7%-2.4pp | 26.2%-3.9pp | 30.1%+8.9pp | 21.2%+17.1pp | 4.1%-18.5pp | ||
| $53.4M+87.4% | $28.5M-46.0% | $52.8M+280% | $13.9M+256% | -$8.9M— | ||
| $28.6M— | —— | —— | —— | $0— | ||
| $246.8M+3.1% | $239.4M-18.0% | $291.8M+82.9% | $159.5M+985% | $14.7M-91.0% | ||
| $48.9M-42.9% | $85.7M+4.1% | $82.3M+58.3% | $52M+665% | $6.8M-88.6% | ||
| $197.9M+28.8% | $153.7M-26.6% | $209.5M+94.9% | $107.5M+1,261% | $7.9M-92.3% | ||
| 24.3%+5.2pp | 19.1%-7.3pp | 26.4%+10.7pp | 15.6%+14.3pp | 1.4%-15.0pp | ||
| $1.91+29.1% | $1.48-27.5% | $2.04+92.5% | $1.06+1,225% | $0.08-92.0% | ||
| $1.97+27.9% | $1.54-27.0% | $2.11+93.6% | $1.09+1,263% | $0.08-92.2% | ||
| 103.4M+0.9% | 102.5M0.0% | 102.5M+1.5% | 101M-1.5% | 102.5M-1.2% | ||
| 100.5M+1.0% | 99.5M+0.1% | 99.4M+0.4% | 99M-0.7% | 99.7M-0.7% | ||
| $25.3M— | —— | $30.6M+557% | -$6.7M+78.1% | -$30.6M-1,511% | ||
| $28.1M+8.9% | $25.8M+16.2% | $22.2M+7.8% | $20.6M-5.1% | $21.7M-3.6% | ||
| $185.2M+20.6% | $153.6M-26.9% | $210.2M+89.4% | $111M+900% | $11.1M-88.2% | ||
| $7.2M+12.5% | $6.4M-4.5% | $6.7M+6.3% | $6.3M-4.5% | $6.6M+6.5% | ||
| $28.6M— | —— | —— | —— | $0— | ||
| $300K-96.2% | $7.8M+609% | $1.1M-98.5% | $71.9M+11,883% | $600K-99.2% | ||
| -$14.3M-119% | $76.5M+37.1% | $55.8M+80.6% | $30.9M+1,130% | -$3M-104% | ||
| $81.4M— | —— | $132.3M+66.0% | $79.7M+116% | $36.9M— | ||
| -$4.3M-226% | $3.4M-72.4% | $12.3M+686% | -$2.1M-224% | $1.7M-85.3% | ||
| -$12.7M— | $0+100% | -$900K-133% | $2.7M+58.8% | $1.7M+133% | ||
| $9.1M— | $0-100% | $13.2M+5.6% | $12.5M+16.8% | $10.7M+46.6% | ||
| $23.6M-36.7% | $37.3M-18.2% | $45.6M+217% | $14.4M-55.1% | $32.1M+221% | ||
| $21.2M+24.7% | $17M+5,567% | $300K— | $0-100% | $100K-96.7% | ||
| $296.2M+14.7% | $258.2M+3.3% | $250M+2.3% | $244.3M-7.2% | $263.2M+41.8% | ||
| $814.5M+1.1% | $805.5M+1.3% | $794.9M+15.6% | $687.5M+20.1% | $572.6M-8.8% | ||
| $57.2M-2.4% | $58.6M+9.1% | $53.7M+1.7% | $52.8M0.0% | $52.8M-20.5% | ||
| $193.4M-8.3% | $210.9M-11.8% | $239M+64.1% | $145.6M+517% | $23.6M-83.4% | ||
| $200.7M-8.1% | $218.4M-11.5% | $246.7M+61.3% | $152.9M+390% | $31.2M-79.1% | ||
| $200.7M-8.1% | $218.4M-11.5% | $246.7M+61.3% | $152.9M+390% | $31.2M-79.1% | ||
| 24.6%-2.5pp | 27.1%-3.9pp | 31%+8.8pp | 22.2%+16.8pp | 5.4%-18.3pp | ||
| $193.4M-8.3% | $210.9M-11.8% | $239M+64.1% | $145.6M+517% | $23.6M-83.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Neurocrine Biosciences's revenue?
- Neurocrine Biosciences (NBIX) generated $3.1B in revenue over the trailing twelve months, up 28.6% year over year.
- Is Neurocrine Biosciences profitable?
- Neurocrine Biosciences reported $668.6M in net income over the trailing twelve months, a 21.6% net margin.
- What are Neurocrine Biosciences's profit margins?
- Gross margin is 98.2% and operating margin is 25.4%, with a 21.6% net margin.
- What is Neurocrine Biosciences's earnings per share?
- Neurocrine Biosciences's diluted EPS over the trailing twelve months is $6.49.
- Where does Neurocrine Biosciences's income statement data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
